Literature DB >> 27296835

Age-related survival disparity associated with lung transplantation in cystic fibrosis: An analysis of the registry of the International Society for Heart and Lung Transplantation.

Don Hayes1, Allan R Glanville2, David McGiffin3, Joseph D Tobias4, Dmitry Tumin5.   

Abstract

BACKGROUND: A survival advantage has been demonstrated for lung transplantation (LTx) in the cystic fibrosis (CF) population, but children may be at higher risk of post-transplant mortality than adults.
METHODS: The registry of the International Society for Heart and Lung Transplantation (ISHLT) was queried for lung transplants performed during the period 1998 to 2014 in patients with CF. Period differences were assessed by dividing the sample into LTxs performed between 2006 and 2014 and those performed between 1998 and 2005. Age ≥18 years distinguished adult from pediatric recipients. Supplemental analyses of United States of America (USA) LTx recipients with CF utilized 1998 to 2014 data from the United Network for Organ Sharing (UNOS) registry.
RESULTS: A total of 7,245 patients from the ISHLT registry were selected for analysis. Kaplan-Meier curves confirmed a survival disadvantage of children as compared to adults with CF in 2006 to 2014 (p<0.001), and in the earlier era of 1998 to 2005 (p = 0.002). Univariate Cox proportional hazards regression revealed that age <18 years at transplantation [hazard ratio (HR) = 1.367; 95% confidence interval (CI) 1.225 to 1.526; p < 0.001] and LTxs performed in 1998 to 2005 (HR = 1.131; 95% CI 1.042 to 1.227; p = 0.003) were associated with greater mortality hazard. Multivariable Cox regression adjusting for potential confounders and interacting LTx era with recipient age group confirmed the persistence of age-related survival disparities after LTx in CF in the contemporary era. Analysis of UNOS data demonstrated survival disparities between children and adult CF patients receiving LTx in majority-adult programs.
CONCLUSIONS: An age-related survival disparity after LTx has persisted in the international CF population. Data from the USA suggest this disparity is not fully explained by differences in center volume between adult and pediatric programs in the contemporary era.
Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adult; age; children; cystic fibrosis; lung transplantation; pediatric; survival

Mesh:

Year:  2016        PMID: 27296835     DOI: 10.1016/j.healun.2016.04.015

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

Review 1.  The Evolution of Lung Transplant Immunosuppression.

Authors:  Steven Ivulich; Glen Westall; Michael Dooley; Gregory Snell
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 2.  Immunosuppression Drug Therapy in Lung Transplantation for Cystic Fibrosis.

Authors:  Pamela Burcham; Lisa Sarzynski; Sabrina Khalfoun; Kimberly J Novak; Julie C Miller; Dmitry Tumin; Don Hayes
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

3.  Early Mortality for Children on Extracorporeal Membrane Oxygenation at Lung Transplant: True or Due to Confounding Variables?

Authors:  Don Hayes
Journal:  Ann Am Thorac Soc       Date:  2022-07

4.  Lung Transplant Index: A Quality Improvement Initiative.

Authors:  Don Hayes; Bob Feeney; Donna J O'Connor; Kerri L Nicholson; Ashley E Nance; Kelly K Sakellaris; Nicole R Dempster; Jaclyn D Groh; Stephen E Kirkby
Journal:  Pediatr Qual Saf       Date:  2019-09-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.